AgingResearch.NewsJoin free

Renal complications

There are 15 papers on renal complications in aging research: 7 observational studies in people, 7 reviews. The newest story, Nov 7, 2026: “Semaglutide linked to fewer events in obesity with poor heart pumping”.

Disease

15 papers study it66 more mention it3 findings

13 new papers in 30 daysSee all 81 papers on renal complications

“demonstrated elevated risks of renal complications (aOR: 1.284, 95% CI: 1.132-1.458)”
Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker ImplantationPreprint2024doi:10.22541/au.172533736.65539101/v1
  • Humans7
  • In silico1

Associations

3

Therapeutic nonresponse

upin humans1

1 study

  1. Therapeutic nonresponse is associated with renal complications in humans (Type 2 diabetes mellitus receiving metformin-sulfonylurea therapy).

    “Renal complications were more prevalent among non-responders (p = 0.029).”

    HumansType 2 diabetes mellitus receiving metformin-sulfonylurea therapy

    Clinical and computational exploration of IRS1 and Pancreastatin genetic variants in metabolic response to metformin-sulfonylurea therapy

    Personalized medicine

Tirzepatide

upin humans1

1 study

  1. Tirzepatide is associated with renal complications in humans (tirzepatide use in aesthetic settings) (Rare; documented mainly in case reports).

    “It was concluded that renal complications are rare and documented mainly in case reports but may be clinically severe.”

    Reviewtirzepatide use in aesthetic settingskidney

    INDISCRIMINATE USE OF TIRZEPATIDE IN AESTHETIC CLINICS: POSSIBLE RENAL COMPLICATIONS IN INDIVIDUALS WITH METABOLIC COMORBIDITIES AND EXCESS BODY WEIGHT

    Revista Ibero-Americana de Humanidades, Ciências e Educação

More on Tirzepatide

Obesity

upin humans1

1 study

  1. Obesity is linked with a higher risk of renal complications in frail patients undergoing LPM implantation (aOR 1.284, 95% CI 1.132-1.458).

    “demonstrated elevated risks of renal complications (aOR: 1.284, 95% CI: 1.132-1.458)”

    Humansin frail patients undergoing LPM implantationn = 6,120

    Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation Body Mass Index, Frailty, and Outcomes in Leadless Pacemaker Implantation

    Preprint

More on Obesity

Funding

2 grants since 2019

National Heart, Lung, and Blood Institute$223KJapan Society for the Promotion of Science¥4.7M

Latest

Dec 2025: 1Jan 2026: 3Feb 2026: 3Mar 2026: 8Apr 2026: 1May 2026: 0Jun 2026: 2Jul 2026: 2Aug 2026: 5Sep 2026: 5Oct 2026: 8Nov 2026: 442 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Semaglutide linked to fewer events in obesity with poor heart pumping

Semaglutide was linked to 40% lower relative risk of major cardiovascular events over 365 days than nonuse in adults with obesity and heart failure with reduced ejection…Semaglutide was linked to 40% lower relative risk of major cardiovascular events over 365 days than nonuse in adults with obesity and heart failure with reduced ejection fraction.

Cohort studySemaglutide
Paper

See all 81 papers on renal complications

Related